Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187465 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL22729341 | 0.86 | CTSS (0.46) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL17371252 | 0.86 | MEN1 (0.49) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL29813445 | 0.85 | CTSS (0.51) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL6762393 | 0.84 | SYK (0.54) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL21222698 | 0.84 | HTT (0.49) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL8427919 | 0.83 | MEN1 (0.53) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL14151477 | 0.83 | CTSS (0.49) | SMN1; SMN2CTSSLMNAMEN1KMT2A | |
| SCHEMBL733157 | 0.82 | LMNA (0.71) | SMN1; SMN2LMNAMEN1KMT2AHTT | |
| SCHEMBL22729349 | 0.82 | CYP3A4 (0.49) | SMN1; SMN2CTSSLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4083051-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-114867734-A | Method for synthesizing peptide compound | 中外制药株式会社 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | VIP, NGLY1, NPPA | SMN1; SMN2 4018/4885CTSS 231/4885LMNA 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.